NASDAQ:TVTX

Travere Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy TVTX

*Your capital is at risk

$55.95

+0.84 (+1.52%)

At Close: Jun 23, 2026

Travere Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -67.55. In total, the insiders bought 700K and sold 260.17K TVTX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-67.55
● Buy	700K shares
● Sell	260.17K shares
73% Buy Activity Moderate Negative Correlation
Sell Signal High Confidence Feb 03, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -67.55. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 22, 2026 Sell	Common Stock G-Gift	Inrig Jula Chief Medical Officer	Officer	468 Value: $0
Jun 12, 2026 Sell	Common Stock S-Sale	Baynes Roy D. Director	Director	4 500 Value: $225.0K
Jun 12, 2026 Buy	Common Stock M-Exempt	Baynes Roy D. Director	Director	4 500 Value: $96.2K
Jun 12, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Coughlin Timothy Director	Director	10 000 Value: $265.2K
Jun 12, 2026 Sell	Common Stock S-Sale	Coughlin Timothy Director	Director	10 000 Value: $500.7K
Jun 12, 2026 Buy	Common Stock M-Exempt	Coughlin Timothy Director	Director	10 000 Value: $265.2K
Jun 12, 2026 Buy	Stock option (right to buy) M-Exempt	Baynes Roy D. Director	Director	4 500 Value: $96.2K
May 19, 2026 Buy	Common Stock A-Award	Williams Brinkley Ruth Director	Director	4 000 Value: $169.0K
May 19, 2026 Buy	Stock option (right to buy) A-Award	Squarer Ron Director	Director	12 000 Value: $507.1K
May 19, 2026 Buy	Stock option (right to buy) A-Award	Poole Sandra Director	Director	12 000 Value: $507.1K
May 19, 2026 Buy	Stock option (right to buy) A-Award	Bruhn Suzanne Louise Director	Director	12 000 Value: $507.1K
May 19, 2026 Buy	Common Stock A-Award	Bruhn Suzanne Louise Director	Director	4 000 Value: $169.0K
May 19, 2026 Buy	Stock option (right to buy) A-Award	Coughlin Timothy Director	Director	12 000 Value: $507.1K
May 19, 2026 Buy	Common Stock A-Award	Coughlin Timothy Director	Director	4 000 Value: $169.0K
May 19, 2026 Buy	Stock option (right to buy) A-Award	Lyons Gary A Director	Director	12 000 Value: $507.1K
May 19, 2026 Buy	Common Stock A-Award	Lyons Gary A Director	Director	4 000 Value: $169.0K
May 19, 2026 Buy	Stock option (right to buy) A-Award	Meckler Jeffrey A Director	Director	12 000 Value: $507.1K
May 19, 2026 Buy	Stock option (right to buy) A-Award	Baynes Roy D. Director	Director	12 000 Value: $507.1K
May 19, 2026 Buy	Common Stock A-Award	Baynes Roy D. Director	Director	4 000 Value: $169.0K
May 19, 2026 Buy	Common Stock A-Award	Poole Sandra Director	Director	4 000 Value: $169.0K
May 19, 2026 Buy	Common Stock A-Award	Squarer Ron Director	Director	4 000 Value: $169.0K
May 19, 2026 Buy	Stock option (right to buy) A-Award	Williams Brinkley Ruth Director	Director	12 000 Value: $507.1K
May 19, 2026 Buy	Common Stock A-Award	Meckler Jeffrey A Director	Director	4 000 Value: $169.0K
May 19, 2026 Buy	Stock option (right to buy) A-Award	Orwin John A Director	Director	12 000 Value: $507.1K
May 19, 2026 Buy	Common Stock A-Award	Orwin John A Director	Director	4 000 Value: $169.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT TRAVERE THERAPEUTICS, INC.

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzy...

Read Full Profile Here